Nucleos(t)ide reverse transcriptase inhibitor-sparing regimens in the era of standard 3-drug combination therapies for HIV-1 infection-Reference-Cited by-同舟云学术

Nucleos(t)ide reverse transcriptase inhibitor-sparing regimens in the era of standard 3-drug combination therapies for HIV-1 infection

Published:2020-12-31 Issue:6 Volume:2 Page:384-387
ISSN:2434-9186
Container-title:Global Health & Medicine
language:en
Short-container-title:GHM

Author:

Uchitsubo Keita¹,Masuda Junichi¹,Akazawa Tsubasa¹,Inoue Risako¹,Tsukada Kunihisa²,Gatanaga Hiroyuki²,Terakado Hiroyuki¹,Oka Shinichi²

Affiliation:

1. Pharmaceutical Department, National Center for Global Health and Medicine, Tokyo.

2. AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo.

Publisher

National Center for Global Health and Medicine (JST)

Link

https://www.jstage.jst.go.jp/article/ghm/2/6/2_2020.01065/_pdf

Reference11 articles.

1. 1. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. https://aidsetc.org/resource/guidelines-use-antiretroviral-agents-hiv-1-infected-adults-and-adolescents (accessed May 27, 2020).

2. 2. Taiwo B, Zheng L, Gallien S, Matining RM, Kuritzkes DR, Wilson CC, Berzins BI, Acosta EP, Bastow B, Kim PS, Eron JJ Jr. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS. 2011; 25:2113-2122.

3. 3. Calza L, Danese I, Magistrelli E, Colangeli V, Manfredi R, Bon I, Re MC, Conti M, Viale P. Dual raltegravir–darunavir/ritonavir combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy including a ritonavir-boosted protease inhibitor plus two nucleoside/nucleotide reverse transcriptase inhibitors. HIV Clin Trials. 2016; 17:38-47.

4. 4. Llibre JM, Hung CC, Brinson C, Castelli F, Girard PM, Kahl LP, Blair EA, Angelis K, Wynne B, Vandermeulen K, Underwood M, Smith K, Gartland M, Aboud M. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 2018; 391:839-849.

5. 5. Nishijima T, Gatanaga H, Shimbo T, et al. Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: A randomized multicenter trial. PLoS One. 2013; 8:e73639.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding the Actual Use of Anti-HIV Drugs in Japan from 2016 to 2019: Demonstrating Epidemiological Relevance of NDB Open Data Japan for Understanding Japanese Medical Care;International Journal of Environmental Research and Public Health;2022-09-25